Radiodermatitis Market to Grow with a CAGR of 3.14% through 2028
Rising incidence of cancer and growing geriatric population
are factors driving the global Radiodermatitis market in the forecast period
2024-2028
According to TechSci Research report, “Radiodermatitis
Market – Global Industry Size, Share, Trends, Competition Forecast &
Opportunities, 2028”, the Global Radiodermatitis Market stood at USD 472.35
Million in 2022 and is anticipated to grow with a CAGR of 3.14% in the forecast
period, 2024-2028. Radiodermatitis, a common side
effect of radiation therapy, is a painful condition that affects cancer
patients during their treatment. The global radiodermatitis market has been
steadily growing over the years, primarily due to an increasing incidence of
cancer cases, advancements in radiation therapy techniques, and a greater focus
on improving patient quality of life. The most significant driver for the radiodermatitis
market is the increasing prevalence of cancer worldwide. Cancer is a leading
cause of mortality and morbidity, and as the global population continues to
grow and age, the number of cancer cases is also on the rise. With radiation
therapy being a crucial component in cancer treatment, the incidence of
radiodermatitis is expected to rise in parallel. Advancements in radiation therapy have
played a pivotal role in the growth of the radiodermatitis market. Modern
radiation therapy techniques, such as intensity-modulated radiation therapy
(IMRT), stereotactic body radiation therapy (SBRT), and proton therapy, offer
more precise and effective cancer treatment. While these techniques are
beneficial in targeting cancer cells, they can still affect the surrounding
healthy skin, leading to radiodermatitis. The development of these advanced
radiation therapies has created a need for more effective radiodermatitis
management solutions.
Rising awareness among healthcare
professionals and patients about radiodermatitis and its impact on the quality
of life has led to early diagnosis and proactive management. Healthcare
providers are increasingly emphasizing the importance of patient education
regarding skincare and prevention. Early diagnosis allows for the
implementation of preventive measures and more effective treatment strategies,
thereby driving the demand for radiodermatitis management products. The
global population is aging, and the elderly population is more prone to cancer.
Older patients often require radiation therapy for their cancer treatment,
making them more susceptible to radiodermatitis. As a result, the growing
geriatric population is contributing to the expansion of the radiodermatitis
market. The Global Radiodermatitis Market is segmented into product, distribution
channel and company. Based on distribution channel, the Hospital Pharmacy segment has
emerged as the predominant market leader. Hospitals often collaborate with researchers and
clinicians to develop and test new products for radiodermatitis management.
This dynamic environment fosters innovation, resulting in the continuous
improvement of treatment options for patients. Hospital pharmacies are committed
to patient-centered care, focusing on the individual needs of each patient.
This approach ensures that patients receive personalized advice and treatment
options, enhancing their overall experience and outcomes.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Radiodermatitis Market.”
Based on region, North America segment is expected to
grow during the forecast period. North America faces a relatively
high incidence of cancer, leading to a larger population of cancer patients
undergoing radiation therapy. As radiodermatitis is directly linked to
radiation exposure, this increases the demand for radiodermatitis management
products in the region The governments of the United States and Canada, along
with private healthcare institutions, invest significantly in cancer research
and patient care. This commitment has led to an environment conducive to the
growth of the radiodermatitis market. The Asia Pacific region is experiencing rapid market
growth. Patients in Asia Pacific have relatively easy access
to healthcare facilities, which enhances the diagnosis and management of
radiodermatitis. Furthermore, healthcare providers in the region are
well-informed about the latest advancements in radiodermatitis treatment and
prevention.
Major companies operating in Global Radiodermatitis Market
are:
- 3M Company
- Bausch Health Companies Inc.
- Bayer AG
- BMG PHARMA S.p.A.
- Charles River Laboratories International
Inc.
- ConvaTec Group plc
- Helsinn Healthcare SA
- ICON plc
- Integra LifeSciences
- Molnlycke Health Care AB
- Stratpharma AG
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The global radiodermatitis market is on a growth
trajectory, primarily due to the increasing incidence of cancer, advancements
in radiation therapy techniques, greater awareness, and supportive government
initiatives. As the market continues to expand, it is crucial for stakeholders
in the healthcare industry to invest in research and development, thereby
ensuring that patients receive the best possible care and management options
for radiodermatitis.,” said Mr. Karan Chechi, Research Director with TechSci
Research, a research-based management consulting firm.
“Radiodermatitis Market By Product
(Topical(Corticosteroids, Hydrophilic Creams, Antibiotics, Others), oral,
dressings (Hydrogel and Hydrocolloid Dressings, No Sting Barrier Film, Honey
Impregnated Gauze, Silicone Coated Dressings, Others)), By Distribution Channel
(Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region, By
Competition Forecast & Opportunities, 2018-2028F”, has evaluated
the future growth potential of Global Radiodermatitis Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Radiodermatitis Market.
Contact
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel:
+13322586602
Email:
[email protected]
Website:
www.techsciresearch.com